Mitsubishi Chemical has given Bain right of first refusal to negotiate sale of its subsidiary, Nikkei says
20/01/2025 10:07
TOKYO, Jan 20 (Reuters) - Mitsubishi Chemical Group 4188.T has given
the U.S. investment fund Bain Capital the right of first refusal to negotiate
the sale of its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, the Nikkei
reported on Monday.
(Reporting by Kaori Kaneko; Editing by Toby Chopra)
((kaori.kaneko@thomsonreuters.com;))
Recent news on Mitsubishi Chemical
See all newsJapan state-backed fund considering sale of chipmaking materials maker JSR, sources say
Japan state-backed fund considering sale of chipmaking materials maker JSR, sources say
Brief: Mitsubishi Chemical Group Corp - Notice Regarding Commencement Of Consideration On Spin-Off Of Petrochemicals Business As A Wholly Owned Subsidiary
Bain-backed Tanabe Pharma targets three new drug launches a year in Japan
2025/26 group results (IFRS)